1Tsujino K, Hirota S, Kotani Y, et al. Radiation pneumonitis following concurrent accelerated hypeffractionted radiotherapy andchemothera- py for limited small-cell lung cancer: dose volumeHis-togram analy- sis and corn parison with conventional ehemoradi-ation[ J]. Int J Radiat Oneol Biol Phys,2006,64 : 1100 - 1105.
2Evans E S, Kocak Z, Zhou S M, et al. Does transforming growth factor betal predict for radiation induced pneumonitis in patient treated for lung cancer [ J ]. Cytokine,2006,35 (3 - 4 ) : 186 - 192.
2Bradley J, Graham MV, Winter K, et al. Toxicity and out-come results of RTOG 9311 : a phase I - II doseescalationstudy using three-dimensional conformal radiotherapy in pa-tients with inoperable non-small cell lung carcinoma[ J].Int J Radiat Oncol Biol Phys,2005 ,61 (2) :318-328.
4Vogelius IS,Bentzen S. Clinical factors associated with riskof radiation pneumonitis : A litterature based meta-analysis[J]. Radiotherapy and Oncology, 2010, 96 ( supp) : 125-126.
5Yuan X, Liao Z, Liu Z, et al. Single nucleotide polymor-phism at rsl982073 :T869C of the TGF beta 1 gene is asso-ciated with the risk of radiation pneumonitis in patientswith non-small-cell lung cancer treated with definitive ra-diotherapy [J ] . J Clin Oncol, 2009 ,27 (20) :3370-3378.
6Forquer JA, Rong N, Fakiris A J, et al. Postoperative radiother- apy after surgical resection of thymoma., differing roles in local- ized and regional disease[J]. Int J Radiat Oncol Biol Phys, 2010,76(2) :440-445.
7Nguyen- Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fraefionation in combination with concurrent cisplatin for head and neck carci- nomas in the Radiation Therapy Oneology Group 0129 trial: long-term report of efficacy and toxieity[J]. J Clin Oncol, 2014,32(34) :3858-3866.
